Status:
TERMINATED
A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma
Lead Sponsor:
Morphotek
Conditions:
Metastatic Melanoma
Malignant Metastatic Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate whether therapy with MORAb-028 is safe, effective, and to determine the appropriate dose of MORAb-028 in the treatment of metastatic melanoma.
Detailed Description
Melanoma is a serious form of skin cancer. If untreated, the melanoma can spread beyond the original affected tissue and invade distant tissue and organs. Treatment for metastatic melanoma includes me...
Eligibility Criteria
Inclusion
- Measurable metastatic melanoma that has failed standard therapy
- Males and females greater than or equal to 18 years of age
- Life expectancy of greater than or equal to 3 months
Exclusion
- Significant cardiovascular impairment
- Clinically significant illness, medical condition, surgical history, or laboratory abnormality that could affect the safety of the subject or negatively impact the study results
- Chemotherapy, radiotherapy, or immunotherapy within 3 weeks prior to administration to MORAb-028
Key Trial Info
Start Date :
December 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT01212276
Start Date
December 1 2010
End Date
September 1 2012
Last Update
July 16 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10022